BioWorld

Oct. 14, 2009

Heed All FDA Compliance Efforts, Drugmakers Warned by Panelists

Amarin's $70M: 'Mixing' It up Against Lovaza in Lipid Space

Corcept Raising $18M to Push Corlux Through Final Testing

Other News To Note

Clinic Roundup

Vanda Inks $465M Novartis Deal, but Acquisition Not off the Table

Five months after the surprise FDA approval of schizophrenia drug Fanapt (iloperidone), Vanda Pharmaceuticals Inc. nailed down a partner to launch the product. (BioWorld Today) Read More

Prosensa, GSK: $25M Up Front, Antisense to Make DMD Sense?

Today's news in brief

BioWorld

BioWorld briefs for Dec. 23, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 23, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...